{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T00:59:39Z","timestamp":1693702779204},"reference-count":38,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2015,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>A higher incidence of anemia has been observed during the treatment of hepatitis C virus genotype 1 (HCV-1) infection with pegylated alpha interferon (pegIFN-\u03b1), ribavirin, and telaprevir. We assessed the impacts that concomitant administration of telaprevir and changes in the glomerular filtration rate have on ribavirin plasma levels. The minimum concentrations of ribavirin in plasma (ribavirin<jats:italic>C<\/jats:italic><jats:sub>min<\/jats:sub>) determined during triple therapy including telaprevir were compared with those observed after telaprevir withdrawal and those observed in the same subjects and in a large cohort during a previous course of pegIFN-\u03b1 plus ribavirin. Intensive pharmacokinetic sampling for ribavirin was performed at steady state during the triple-therapy phase. Ribavirin levels were measured by liquid chromatography-tandem mass spectrometry (LC-MS\/MS). Twenty-seven HCV-1\/HIV-coinfected patients were enrolled. The median ribavirin<jats:italic>C<\/jats:italic><jats:sub>min<\/jats:sub>for triple therapy (4.08 \u03bcg\/ml; range, 2.14 to 5.56 \u03bcg\/ml) was higher than that observed after telaprevir withdrawal (1.96 \u03bcg\/ml; range, 0.41 to 3.45 \u03bcg\/ml) (<jats:italic>P<\/jats:italic>&lt; 0.001) and that observed for 125 HCV-1\/HIV-coinfected patients treated only with pegIFN-\u03b1 plus ribavirin (1.65 \u03bcg\/ml; range, 0.41 to 5.56 \u03bcg\/ml) (<jats:italic>P<\/jats:italic>&lt; 0.001). The estimated glomerular filtration rate (eGFR) decreased &gt;20% from the baseline value in 11 of 27 patients and became normal after telaprevir removal in almost all cases. There was a negative correlation between eGFR and ribavirin clearance (<jats:italic>r<\/jats:italic><jats:sup>2<\/jats:sup>= 0.257;<jats:italic>P<\/jats:italic>= 0.064) but not the ribavirin area under the concentration-time curve from 0 to 12 h (AUC<jats:sub>0\u201312<\/jats:sub>) (<jats:italic>r<\/jats:italic><jats:sup>2<\/jats:sup>= 0.001;<jats:italic>P<\/jats:italic>= 0.455). Thus, there is a significant pharmacokinetic interaction between telaprevir and ribavirin that results in very high ribavirin levels, which explains the excess of toxicity observed with this drug combination. A blockade of the proximal tubular transporters might be implicated in both the increase in plasma creatinine and the high ribavirin levels. (This study has been registered at ClinicalTrials.gov under registration no. NCT01818856.)<\/jats:p>","DOI":"10.1128\/aac.04795-14","type":"journal-article","created":{"date-parts":[[2015,3,24]],"date-time":"2015-03-24T02:32:47Z","timestamp":1427164367000},"page":"3257-3262","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":3,"title":["Telaprevir and Ribavirin Interaction: Higher Ribavirin Levels Are Not Only Due to Renal Dysfunction during Triple Therapy"],"prefix":"10.1128","volume":"59","author":[{"given":"Alicia","family":"Gutierrez-Valencia","sequence":"first","affiliation":[{"name":"Enfermedades Infecciosas, Microbiolog\u00eda y Medicina Preventiva, Hospital Universitario Virgen del Roc\u00edo, Seville, Spain"},{"name":"Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla, Seville, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Ruiz-Valderas","sequence":"additional","affiliation":[{"name":"Enfermedades Infecciosas, Microbiolog\u00eda y Medicina Preventiva, Hospital Universitario Virgen del Roc\u00edo, Seville, Spain"},{"name":"Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla, Seville, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar J.","family":"Ben-Marzouk-Hidalgo","sequence":"additional","affiliation":[{"name":"Enfermedades Infecciosas, Microbiolog\u00eda y Medicina Preventiva, Hospital Universitario Virgen del Roc\u00edo, Seville, Spain"},{"name":"Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla, Seville, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Almudena","family":"Torres-Cornejo","sequence":"additional","affiliation":[{"name":"Enfermedades Infecciosas, Microbiolog\u00eda y Medicina Preventiva, Hospital Universitario Virgen del Roc\u00edo, Seville, Spain"},{"name":"Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla, Seville, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Espinosa","sequence":"additional","affiliation":[{"name":"Enfermedades Infecciosas, Microbiolog\u00eda y Medicina Preventiva, Hospital Universitario Virgen del Roc\u00edo, Seville, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan R.","family":"Castillo-Ferrando","sequence":"additional","affiliation":[{"name":"Farmacolog\u00eda Cl\u00ednica, Hospital Universitario Virgen del Roc\u00edo, Seville, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pompeyo","family":"Viciana","sequence":"additional","affiliation":[{"name":"Enfermedades Infecciosas, Microbiolog\u00eda y Medicina Preventiva, Hospital Universitario Virgen del Roc\u00edo, Seville, Spain"},{"name":"Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla, Seville, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis F.","family":"Lopez-Cortes","sequence":"additional","affiliation":[{"name":"Enfermedades Infecciosas, Microbiolog\u00eda y Medicina Preventiva, Hospital Universitario Virgen del Roc\u00edo, Seville, Spain"},{"name":"Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla, Seville, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.01.027"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1177\/135965350701200815","article-title":"Early monitoring of ribavirin serum concentration is not useful to optimize hepatitis C virus treatment in HIV-coinfected patients","volume":"12","author":"Crespo M","year":"2007","unstructured":"Crespo M, Pou L, Esteban JI, Falc\u00f3 V, Ribera E, Lopez R, Sauleda S, Curran A, Villar del Saz S, Feijoo M, Oca\u00f1a I, Pahissa A. 2007. Early monitoring of ribavirin serum concentration is not useful to optimize hepatitis C virus treatment in HIV-coinfected patients. Antivir Ther 12:1217\u20131223.","journal-title":"Antivir Ther"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn013"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22217"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.110"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/135965350801300401","article-title":"Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients","volume":"13","author":"Maynard M","year":"2008","unstructured":"Maynard M, Pradat P, Gagnieu MC, Souvignet C, Trepo C. 2008. Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients. Antivir Ther 13:607\u2013611.","journal-title":"Antivir Ther"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03705.x"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.04065.x"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr034"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.01.059"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2010.01399.x"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis449"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12128"},{"key":"e_1_3_2_15_2","unstructured":"US Food and Drug Administration. 2012. Telaprevir full prescribing information. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/201917s007lbl.pdf."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2012.12.017"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.04.035"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12086"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12170"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12162"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26602"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26730"},{"key":"e_1_3_2_23_2","volume-title":"Abstr 21st Conf Retroviruses Opportunistic Infect","author":"Cotte L","year":"2014","unstructured":"Cotte L, Barrail-Tran A, Vincent C, . 2014. Telaprevir increases ribavirin toxicity through eGFR decrease in HIV-HCV-coinfected patients, abstr 664LB. Abstr 21st Conf Retroviruses Opportunistic Infect, Boston, MA."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2012.02782.x"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit693"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23624"},{"key":"e_1_3_2_27_2","first-page":"S17","article-title":"The clinical pharmacology of ribavirin","volume":"19","author":"Glue P","year":"1999","unstructured":"Glue P. 1999. The clinical pharmacology of ribavirin. Semin Liver Dis 19(Suppl 1):S17\u2013S24.","journal-title":"Semin Liver Dis"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011945103455"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.5582\/ddt.8.89"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2012.07.032"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2014.66"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.300.3.918"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00251-06"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.111.042036"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2013.07.008"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2006.02.012"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1998.00836.x"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01780.x"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1991.162"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.04795-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.04795-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T19:12:12Z","timestamp":1651605132000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.04795-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.1128\/AAC.04795-14"],"URL":"https:\/\/doi.org\/10.1128\/aac.04795-14","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"2014-11-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-03-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-05-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}